iCaspase 9 suicide gene system

Methods in Molecular Biology

Volumn 1317, Issue , 2015, Pages 87-105

  Zhou, Xiaoou ^a   Di Stasi, Antonio ^a   Brenner, Malcolm K ^a  

^a NONE

Author keywords

Allodepleted T cells; AP1903; Dimerizer; GvHD; Inducible caspase 9; Safety switch; Suicide gene

Indexed keywords

BINDING PROTEIN; CASPASE 9; INDUCIBLE CASPASE 9; RIMIDUCID; UNCLASSIFIED DRUG; CD3 ANTIGEN; FIBRONECTIN; IMMUNOTOXIN; INTERLEUKIN 2; OKT 3; RECOMBINANT PROTEIN; RETRONECTIN;

ANTIGEN SPECIFICITY; APOPTOSIS; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DIMERIZATION; DRUG ACTIVATION; GENE FUSION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LYMPHOCYTE FUNCTION; MOLECULAR SIZE; MOLECULAR STABILITY; PHENOTYPE; PRIORITY JOURNAL; SUICIDE GENE THERAPY; T LYMPHOCYTE; CELL PROLIFERATION; CLINICAL TRIAL; COCULTURE; CYTOLOGY; DONOR; DRUG EFFECTS; FLOW CYTOMETRY; GENETIC TRANSDUCTION; IMMUNOLOGY; LEUKOCYTE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; METABOLISM; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RETROVIRIDAE; SUICIDE TRANSGENE; TRANSGENE;

ANTIGENS, CD3; CASPASE 9; CELL PROLIFERATION; COCULTURE TECHNIQUES; FIBRONECTINS; FLOW CYTOMETRY; GENES, TRANSGENIC, SUICIDE; HUMANS; IMMUNOTOXINS; INTERLEUKIN-2; LEUKOCYTES; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; MUROMONAB-CD3; RECOMBINANT PROTEINS; RETROVIRIDAE; T-LYMPHOCYTES; TISSUE DONORS; TRANSDUCTION, GENETIC; TRANSGENES;

EID: 84931262138     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4939-2727-2_6     Document Type: Article

References (24)

1. Walter EA, Greenberg PD, Gilbert MJ et al (1995) Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 333: 1038–1044
2. Rooney CM, Smith CA, Ng CY et al (1998) Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 92:1549–1555
3. Dudley ME, Wunderlich JR, Robbins PF et al (2002) Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298:850–854
4. Bonini C, Ferrari G, Verzeletti S et al (1997) HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 276:1719–1724
5. Ciceri F, Bonini C, Marktel S et al (2007) Antitumor effects of HSV-TK–engineered donor lymphocytes after allogeneic stem-cell transplantation. Blood 109:4698–4707
6. Tiberghien P, Ferrand C, Lioure B et al (2001) Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-celldepleted allogeneic marrow graft. Blood 97: 63–72
7. Ciceri F, Bonini C, Stanghellini MT et al (2009) Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. Lancet Oncol 10:489–500
8. Traversari C, Marktel S, Magnani Z et al (2007) The potential immunogenicity of the TK suicide gene does not prevent full clinical benefi t associated with the use of TK-transduced donor lymphocytes in HSCT for hematologic malignancies. Blood 109:4708–4715
9. Garin MI, Garrett E, Tiberghien P et al (2001) Molecular mechanism for ganciclovir resistance in human T lymphocytes transduced with retroviral vectors carrying the herpes simplex virus thymidine kinase gene. Blood 97:122–129
10. Spencer DM, Wandless TJ, Schreiber SL, Crabtree GR (1993) Controlling signal transduction with synthetic ligands. Science 262: 1019–1024
11. Schreiber SL (1991) Chemistry and biology of the immunophilins and their immunosuppressive ligands. Science 251:283–287
12. Clipstone NA, Crabtree GR (1992) Identifi cation of calcineurin as a key signalling enzyme in T-lymphocyte activation. Nature 357:695–697
13. Clackson T, Yang W, Rozamus LW et al (1998) Redesigning an FKBP-ligand interface to generate chemical dimerizers with novel specifi city. Proc Natl Acad Sci U S A 95:10437–10442
14. Iuliucci JD, Oliver SD, Morley S et al (2001) Intravenous safety and pharmacokinetics of a novel dimerizer drug, AP1903, in healthy volunteers. J Clin Pharmacol 41:870–879
15. Straathof KC, Pulè MA, Yotnda P et al (2005) An inducible caspase 9 safety switch for T-cell therapy. Blood 105(11):4247–4254
16. Tey SK, Dotti G, Rooney CM, Heslop HE, Brenner MK (2007) Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. Biol Blood Marrow Transplant 13(8):913–924
17. Di Stasi A, Tey SK, Dotti G et al (2011) Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 365(18):1673–1683
18. Montagna D, Yvon E, Calcaterra V et al (1999) Depletion of alloreactive T cells by a specifi c anti-interleukin-2 receptor p55 chain immunotoxin does not impair in vitro antileukemia and antiviral activity. Blood 93(10):3550–3557
19. André-Schmutz I, Le Deist F, Hacein-Bey- Abina S et al (2002) Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation: a phase 1/2 study. Lancet 360(9327):130–137
20. Amrolia PJ, Muccioli-Casadei G, Yvon E et al (2003) Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses. Blood 102(6):2292–2299
21. Amrolia PJ, Muccioli-Casadei G, Huls H et al (2006) Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation. Blood 108(6):1797–1808
22. Schnell R, Vitetta E, Schindler J et al (1998) Clinical trials with an anti-CD25 ricin A-chain experimental and immunotoxin (RFT5- SMPT- dgA) in Hodgkin’s lymphoma. Leuk Lymphoma 30(5–6):525–537
23. Zhou X, Di Stasi A, Tey SK et al (2014) Longterm outcome and immune reconstitution after haploidentical stem cell transplant in recipients of allodepleted-T-cells expressing the inducible caspase-9 safety transgene. Blood 123(25): 3895–3905
24. Böyum A (1968) Isolation of mononuclear cells and granulocytes from human blood. Scand J Clin Lab Invest Suppl 97:77–89